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Abstract
Dupuytren’s Disease (DD) is a benign fibrosis of the palmar fascia, the connective tissue
beneath the skin of palm and digits. DD leads to loss of hand function and affects 4 - 6% of the
US population alone. Current treatments focus on removing diseased tissue through surgery —
however, post-surgery disease recurrence rates exceed 30% with no known cure. Previous
studies found that fibroproliferative diseases such as DD contain fibroblasts with abnormally
high levels of β-catenin, similar to certain malignancies such as colon cancer. In colon cancer
cells, nuclear translocation of β-catenin trans-activates genes responsible for cellular
proliferation, and this process is facilitated by the transducin β-like proteins TβL1 and TβLR1
that are post-translationally modified with small ubiquitin-like modifiers (SUMOylation). The
anti-cancer drug, BC2059 (Tegavivint), has been developed to competitively inhibit interactions
between β-catenin and SUMOylated TβL1/TβLR1 and is currently undergoing Phase-I clinical
trials. It is currently unknown whether the SUMOylated TβL1/TβLR1 complex mediates βcatenin nuclear translocation in DD. In this study, we investigated whether β-catenin interactions
with SUMOylated TβL1/TβLR1 were present in primary fibroblasts derived from patients with
DD, and if cytokine treatments mimicking inflammation during fibrosis modified these
interactions. Through western blotting, proximity ligation assays, and confocal microscopy, we
confirmed that in DD fibroblasts— the levels of SUMOylated TβL1/TβLR1 increased in
response to cytokines. Moreover, we observed that the interactions between β-catenin and
TβL1/TβLR1 were significantly increased. The novel finding of cytokine-induced SUMOylation
of TβL1/TβLR1 presents a mechanistic link between inflammation and fibroproliferation. Given
the prevalence and debilitating nature of DD, there exists a need to identify new therapeutic
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targets to prevent disease progression and recurrence — the results of this study identify
SUMOylated TβL1/TβLR1 interactions with β-catenin as a feasible target and provide a strong
rationale to cross-purpose anti-cancer drugs such as BC2059 to treat DD.
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Introduction
Dupuytren’s Disease
Dupuytren’s Disease (DD) is a chronic, heritable fibrosis of the palmar fascia —the
fibrous layer of connective tissue found underneath the skin of the palm and digits. During the
progression of DD, the palmar fascia undergoes excessive deposition of collagen, eventually
thickening to the point where some patients experience permanent hand and/or finger
contractures1. The prevalence of DD is estimated to be up to 7% in the United States of America,
and as high as 32% in some regions of Europe2, 3. Current treatments for DD primarily focus on
directly removing diseased palmar fascia, either through invasive surgical interventions
(fasciectomy), or enzymatic breakdown using minimally invasive collagenase injections1, 4.
Unfortunately, post-surgery disease recurrence rates are high, typically exceeding 30% and as a
result, DD is presently incurable5. Given the prevalence and debilitating nature of DD, there
exists a crucial need to identify new therapeutic targets in order to prevent disease progression
and recurrence.

Canonical β-catenin signalling
Although DD is ultimately benign, it shares certain molecular characteristics with
malignant tumours, particularly increased β-catenin levels 6. β-catenin is a dual function transactivating factor that regulates gene transcription and coordinates cell-to-cell adhesion7. It is
normally under regulation and tagged for degradation through phosphorylation through a
destruction complex consisting of the scaffolding proteins Axin, Adenoma Polyposis Coli
(APC), glycogen synthase kinase 3β (GSK3β), and casein kinase 1 (CK1). Ultimately,
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phosphorylated β-catenin undergoes degradation through the 26S proteasome ubiquitination
pathway 7. Inactivation of the destruction complex occurs canonically through Wnt-signalling,
where β-catenin accumulates in the cytoplasm and translocates into the nucleus to trans-activate
genes involved in cell proliferation, differentiation, and adhesion— normally, this process is
crucial in normal embryonic development7. However, abnormal Wnt-signalling has been
implicated in various malignancies such as colon cancer as a result of mutations in the APC gene
—leading to a dysfunctional destruction complex and over-accumulation of β-catenin in the
cytoplasm6, 7.

The role of β-catenin in normal and abnormal wound healing
Fibroproliferative diseases such as DD are an exaggerated response to wound healing7. In
addition to its role in the development of certain cancers, β-catenin is involved in the normal
wound healing process, which can be characterized by three major phases: the inflammatory
response, the proliferative phase, and the remodelling phase7 (Figure 1). The inflammatory
response is necessary to mediate the break down of debris and clearance of bacteria by
neutrophils and macrophages. To begin the transition from the inflammatory phase to the
proliferative phase, a number of growth factors and anti-inflammatory cytokines such as
transforming growth factors α and β (TGFα and TGFβ), epidermal growth factor (EGF), and
insulin-like growth factor (IGF) are released by macrophages at the wound to stimulate fibroblast
migration and proliferation. During the proliferation phase, recruited fibroblasts differentiate into
myofibroblasts, which then function during the tissue-remodelling phase to deposit collagen
bundles that compact or contract the wound. Notably, within the proliferative phase of normal
wound healing — it is believed that TGFβ mediates β-catenin signalling in fibroblasts through
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inactivation of GSK3β, and that fibroblast proliferation and subsequent tissue remodelling is
dependent on β-catenin signalling. Ultimately, dysregulation of β-catenin-signalling during
fibroblast proliferation may be a factor in the abnormal wound healing response leading to the
development of fibroproliferative disorders such as DD 16, 17, 18.

Previous studies have shown that the fibroblasts inducing palmar fascia fibrosis (DD
fibroblasts) exhibit markedly increased cytoplasmic and nuclear β-catenin levels24. Unpublished
findings in our lab have demonstrated that β-catenin nuclear translocation in DD may lead to its
association with certain pro-fibrotic and pro-malignant genes, such as WT1 (encoding Wilm’s
Tumour One). A high level of the WT1 protein is known to be a common characteristic among
various cancers, and more recently, in DD8, 9. The potential consequences of aberrant β-catenin
nuclear translocation in DD, therefore, make it a valuable therapeutic target to prevent disease
progression and/or recurrence. However, the specific molecular mechanisms that are responsible
for its nuclear translocation are unclear.

Fig 1. The normal wound healing process.
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Mechanisms behind the nuclear translocation of β-catenin
Recently, the conjugation of small ubiquitin-like modifiers (SUMO1) to Transducin βlike 1 (TβL1) and Transducin β-like receptor 1 (TβLR1) have been implicated in the nuclear
translocation of β-catenin in colon cancer cells exhibiting high β-catenin levels and aberrant βcatenin signaling. More specifically, it is believed that only after SUMO1 conjugation
(SUMOylation) of the TβL1/TβLR1 complex will β-catenin associate with the complex and
localize into the nucleus10 (Figure 2). Small molecule inhibitors, such as BC2059 (Tegavivint),
have been developed to competitively inhibit SUMOylated TβL1/TβLR1 interactions with βcatenin as an anti-cancer therapeutic11, and are already in phase I clinical trials28. The aim of this
study was to identify parallels in the molecular characteristics associated between DD and cancer
to determine the feasibility of cross-purposing anti-cancer drugs such as BC2059 for the
treatment of DD and other fibroproliferative disorders.

Based on the findings that there are increased levels of cytoplasmic and nuclear β-catenin
in DD, we hypothesized that in DD, β-catenin nuclear translocation is facilitated by the
SUMOylated TβL1/TβLR1 complex, and that inhibition of this complex will prevent DD
progression and recurrence.
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Fig 2. Nuclear translocation of β-catenin in cancer.
TβL1/TβLR1 SUMOylation induces their dissociation from the Nuclear hormone receptor CoRepressor (NCoR) / Silencing Mediator of Retinoic acid and Thyroid hormone receptor (SMRT)
complex and translocation to the cytoplasm. Cytoplasmic stabilization of ß-catenin by Wnt
promotes the formation of ß-catenin/SUMO-TßL1/SUMO-TßLR1 complexes, translocation to
the nucleus and transactivation of gene transcription. Adapted from Choi et al., (2011).

9

Materials and Methods
Clinical Specimen Collection
Surgically resected palmar fascia tissue samples were obtained from patients with
Dupuytren’s Disease (DD) and patients undergoing surgery for carpal-tunnel release (CT) at the
XXX hospital. All patients signed consent forms allowing their tissues to be used for research,
and the XXX Research Ethics Board approved sample collection for Health Sciences Research
involving Human Subjects (XXX). Lab numbers were assigned to samples prior to processing in
order to meet patient de-identification and confidentiality agreements.

Primary Cell Culture
DD fibroblasts were extracted from the palmar fascia of DD patients, while the palmar
fascia from patients without any history of DD undergoing carpal tunnel release was used to
extract phenotypically normal fibroblasts (CT fibroblasts) for use as allogeneic controls.
Tissue samples were dissected and placed onto 100 mm culture dishes containing α-MEM
medium (Life Technologies) supplemented with 1% antibiotic-antimycotic solution (Life
Technologies), 1% L-Glutamine (Life Technologies), and 10% fetal bovine serum (FBS; Life
Technologies) at 37°C in 5% CO2. The cellular outgrowths from tissue fragments were then
passaged routinely by trypsinization using 0.25% trypsin (Gibco). All primary cell cultures were
used up to a maximum of seven passages, where afterward they were discarded.
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Cytokine Treatments
DD and CT fibroblasts were seeded at a density of 2.2 x 106 cells in 100 mm dishes and
serum-starved in serum-free α-MEM media for at least 24 hours prior to treatment with human
pro-inflammatory cytokine mixtures (Cytomix 1), or human anti-inflammatory cytokine mixtures
(Cytomix 2). The human cytokines comprising Cytomix 1 and 2 were purchased from
PeproTech. Cytomix 1 was comprised of tumour necrosis factor (TNF), interleukin 1 beta (IL1β), and interferon gamma (IFN-γ) at a stock concentration of 1 ug/mL. Cytomix 2 was comprised
of intereukin-4 (IL-4), interleukin 10 (IL-10), and transforming growth factor beta (TGFβ1), at a
stock concentration of 1 ug/mL. DD and CT fibroblasts were treated separately at 24 and 48h
with Cytomix 1 or Cytomix 2, at a dose of 0.5 ng/ml.

Antibodies
The following primary antibodies were used: rabbit polyclonal SUMO1 antibody
(ab11672, Abcam, 1:100 for proximity ligation assays), mouse monoclonal TβL1 antibody (sc137083, SantaCruz 1:150 for immunocytofluorescence and proximity ligation assays), mouse
monoclonal TβLR1 antibody (ab117761, Abcam, 1:150 for immunocytofluorescence and
proximity ligation assays), rabbit monoclonal non-phosphorylated active β-catenin antibody
(D13A1, Cell Signalling Technology, 1:1000 for immunoblotting; 1:200 for proximity ligation
assays). The following secondary antibodies for western immunoblotting were used: horseradish
peroxidase (HRP)-linked horse anti-mouse IgG (#7076, Cell Signaling Technology, 1:1000), and
HRP-linked goat anti-rabbit IgG (#7074, Cell Signaling Technology, 1:1000). For
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immunocytofluorescence, the following secondary antibodies were used: anti-rabbit Alexa Fluor
568 (Molecular Probes, 1:400) and anti-mouse Alexa Fluor 488 (Molecular Probes, 1:400).
Cell Lysate Preparation
Cell pellets stored at -80°C were resuspended in RIPA cell lysis buffer (Teknova)
supplemented with protease inhibitor cocktail (Sigma-Aldrich), 0.1M sodium flouride, 10 mM
sodium orthovanadate, and 10 mM phenylmethane sulfonyl fluoride (PMSF). Resuspended cells
were then needle aspirated five times and placed on ice for 30 minutes. Cell lysates were
centrifuged at 5000 RPM to remove insoluble material, and total protein concentrations were
determined by Bicinchoninic Assay (BCA, ThermoScientific). Protein lysates were used directly
for western immunoblotting.

Western Immunoblotting and Densitometry Analysis
Protein samples were separated using stain-free Mini Protean TGX precast gels (BioRad), and transferred onto a nitrocellulose membrane using the Invitrogen iBlot. Membranes
were visualized by chemiluminescence on a Chemidoc XRS+ (BioRad). Band intensity was
normalized using total protein lane quantification, using the total protein imaged on the stain-free
membrane25. Relative densitometry analysis was performed using ImageLab 6.0 (BioRad).

Immunocytofluorescence
Cells were fixed with 4% paraformaldehyde using Nunc Lab-Tek 8-well chamber slides
(ThermoFisher) at 60-70% confluency. Cells were washed with phosphate-buffered saline (PBS)
three times for five minutes and permeabilised by incubating in 0.1% Triton X-100 in PBS for 30
minutes. Samples were blocked for ten minutes (Background Sniper, Biocare Medical) and then
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rinsed three times for five minutes in PBS. All incubations were completed at room temperature.
Primary antibodies were then added for overnight incubation at 4°C. Alexa Fluor 488 or 568
secondary antibodies were added to the cells for one hour in PBS containing 1% bovine serum
albumin (BSA) and 0.1% Tween-20 detergent, and subsequently washed in PBS for three times
for five minutes in PBS. Glass slides were then mounted onto the chamber slides with Duolink
mounting media containing DAPI counterstain (Sigma-Aldrich).
Images were captured on a Nikon A1R+ hybrid resonant/galvano point scanning confocal
microscope 20X objective lens, using the NIS Elements AR software for data acquisition at room
temperature. The Alexa Fluor 568 was excited with the 15 MW 561 nm diode-pumped solidstate laser, while the Alexa Fluor 488 was excited with the 15 MW 488 nm diode laser. The
DAPI signal was excited using the 15 MW 405 nm diode laser. The system is equipped with four
Photomultiplier tubes for standardized fluorescence detection.

Proximity Ligation Assays (PLA)
Cells were fixed with 4% paraformaldehyde using Nunc Lab-Tek 8-well chamber slides
(ThermoFisher) at 60-70% confluency. Cells were washed with phosphate-buffered saline (PBS)
three times for five minutes and permeabilised by incubating in 0.1% Triton X-100 in PBS for 30
minutes. Cells were then rinsed with three times for five minutes in PBS and then treated with
blocking solution (Duolink Sigma-Aldrich) for 60 minutes at 37°C. All incubations were
completed at room temperature. Primary antibodies were then added for overnight incubation at
4°C. Combinations of each primary antibody are as follows: i) β-catenin rabbit polyclonal CellSignalling technology 9562L (1:200) and TβL1 mouse monoclonal Santa Cruz H-11 (1:100), ii)
β-catenin rabbit polyclonal Cell-Signalling technology 9562L (1:200) and TβLR1 mouse
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monoclonal Abcam 117761 (1:200), iii) TβL1 mouse monoclonal Santa Cruz H-11 (1:100) and
SUMO1 rabbit polyclonal Abcam 11672 (1:400), iv) TβLR1 mouse monoclonal Abcam 117761
(1:200) and SUMO1 rabbit polyclonal Abcam 11672 (1:400). The secondary probes were diluted
1:5 in the antibody diluent (Duolink Sigma-Aldrich) and incubated for one hour at 37°C. The
species of the secondary probes used were Anti-Rabbit PLUS and Anti-mouse MINUS (Duolink
Sigma-Aldrich). The subsequent ligation and amplification reactions were performed according
to the manufacturer’s instructions. Cells were then mounted on slides with mounting media
containing DAPI counterstain (Sigma-Aldrich).
Images were captured on a Nikon A1R+ hybrid resonant/galvano point scanning confocal
microscope 60X objective lens, using the NIS Elements AR software for data acquisition. Five
regions were randomly selected per slide and Z-stack images were captured for quantitative
analysis

Three-Dimensional Analysis of PLA Signals
The 3D analysis was performed using NIS Elements AR software. The default 3Dthresholding function was used to create an iso-surface of the nuclear (DAPI) signals. The PLA
signals were then iso-surfaced using the default 3D spot-detection function. PLA interactions per
cell were calculated by dividing the total number detected PLA signals by the number of cells in
each image (based on DAPI signal).

Statistical Analyses
Statistical analyses were conducted using GraphPad Prism 7 statistical software. For the
immunoblotting experiments, ordinary one-way Analysis of Variance (ANOVA) was used in
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order to determine any significant treatment effects at similar time points for the immunoblotting
experiments, where significance was designated at p < 0.05. When significance was detected,
post-hoc analyses were performed using the Dunnett’s test to compare the effect of each
treatment at a specific time point with a control group at the same time point. For the PLA
experiments, the unpaired T-test was used to determine any significant treatment effects between
treatment and control, where significance was designated at p < 0.05.
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Results
Fibrosis-associated cytokines enhance β-catenin protein levels in DD and CT fibroblasts
As with other fibroproliferative disorders, DD is the result of an exaggerated, abnormal
wound healing response to chronic inflammation7. Therefore, we created cell culture conditions
that would best mimic the chronic inflammatory environment in order to maximize and stabilize
β-catenin levels.
To mimic the pro-inflammatory phase of tissue repair, in which chronic activation is
associated with cytotoxicity and damage 14, we treated DD and CT fibroblasts with a proinflammatory cytokine mixture consisting of TNF (tumour necrosis factor), IL1β (interleukin-1
beta), IFNγ (interferon gamma), termed “Cytomix 1”. To mimic the anti-inflammatory phase of
tissue repair, where inflammation is dampened and tissue remodeling is initiated 14, we treated
DD and CT fibroblasts with an anti-inflammatory cytokine mixture consisting of IL4 (interleukin
4), IL10 (interleukin 10), and TGFβ (transforming growth factor beta), termed “Cytomix 2”. The
concentrations of our cytokine mixtures were dosed at 0.5 ng/ml, approximating the
physiological levels detected in fresh DD tissue15. There were no noticeable differences in the
levels of active β-catenin when treated with Cytomix 1 and 2 at 24 hours, in both DD and CT
fibroblasts (Figure 3B, 4B, respectively). A modest 2-fold increase in β-catenin levels was
observed after Cytomix 1 treatment at 48 hours in DD fibroblasts (Figure 3D), however CT
fibroblasts remained relatively unaffected (Figure 4D). After 48-hour Cytomix 2 treatment, we
observed in DD fibroblasts significant 3-fold increase in β-catenin levels (Figure 3D), and a
significant 2-fold increase in β-catenin levels in CT fibroblasts (Figure 4D). Taken together,
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exposing DD and CT fibroblasts to Cytomix 2 successfully increased β-catenin levels, relative to
Cytomix 1 treatments.

- 92 kDa

- 92 kDa

Fig 3. Anti-inflammatory cytokines (Cytomix 2) increase levels of β-catenin in DD
fibroblasts.
(A, C) Immunoblots for active non-phosphorylated (Ser33/37/Thr41) β-catenin in DD
fibroblasts. All groups were treated cultured in serum-free media for 24 hours prior to treatment.
Treatments: no treatment for 24 hours or 48 hours (NT); TNF, IL1β, IFNγ (Cytomix1) (0.5
ng/ml) added for 24 or 48 hours; IL4, IL10, TGFβ1 (Cytomix2) (0.5 ng/ml) added for 24 or 48
hours. Total protein imaged on the stain-free membrane was used as a loading control to
normalize band intensity. Results are shown from the same probed blot.
(B, D) Relative densitometry analysis for active β-catenin in DD fibroblasts treated with
Cytomix 1 or 2 at 24 and 48 hours, respectively. Data derived from one patient (N=1) assessed in
triplicate (n=3). Total lane protein quantification was used to normalize band intensity.
Densitometry analysis was tested by one-way ANOVA followed by Dunnett’s multiple
comparison test. Asterisks indicate significant differences to control (*P<0.05, *** P<0.0002).
Values shown are mean +/- SD.
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- 92 kDa

- 92 kDa

Fig 4. Anti-inflammatory cytokines increase levels of β-catenin in CT fibroblasts.
(A, C) Immunoblots for active non-phosphorylated (Ser33/37/Thr41) β-catenin in CT
fibroblasts. All groups were cultured in serum-free media for 24 hours prior to treatment.
Treatments: no treatment for 24 hours or 48 hours (NT); TNF, IL1β, IFNγ (Cytomix1) (0.5
ng/ml) added for 24 or 48 hours; IL4, IL10, TGFβ1 (Cytomix2) (0.5 ng/ml) added for 24 or 48
hours. Total protein imaged on the stain-free membrane was used as a loading control to
normalize band intensity. Results are shown from the same probed blot.
(B, D) Relative densitometry analysis for active β-catenin in CT fibroblasts treated with Cytomix
1 or 2 at 24 and 48 hours, respectively. Data derived from one patient (N=1) assessed in triplicate
(n=3). Total lane protein quantification was used to normalize band intensity. Densitometry
analysis was tested by one-way ANOVA followed by Dunnett’s multiple comparison test.
Asterisks indicate significant differences to control (*P<0.05, *** P<0.0002). Values shown are
mean +/- SD.
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Cytoplasmic localizations of TβL1 are increased in DD fibroblasts relative to CT fibroblasts
To assess whether the SUMOylated TβL1/TβLR1 complex facilitates β-catenin nuclear
translocation in DD fibroblasts, the cytoplasmic localization of TβL1 was visualized using
immunofluorescence confocal microscopy. Primary mouse monoclonal antibodies to TβL1 and
Alexa Fluor 568 secondary antibodies were used to visualize the cytoplasmic and nuclear
localization of TβL1 by immunofluorescence confocal microscopy. As demonstrated in Figure
5A, both cytoplasmic and nuclear localization of TβL1 was evident in DD fibroblasts, while
TβL1 localization was found to be predominantly nuclear in CT fibroblasts, as seen in Figure 5B.

TβLR1 localization is cytoplasmic and nuclear in both DD and CT fibroblasts
To assess whether the SUMOylated TβL1/TβLR1 complex facilitates β-catenin nuclear
translocation in DD fibroblasts, the cytoplasmic localization of TβLR1 was visualized using
immunofluorescence confocal microscopy. Primary mouse monoclonal antibodies to TβLR1
and Alexa Fluor 568 secondary antibodies were used to visualize TβLR1 localization by
confocal microscopy. As demonstrated by Figure 6A and 6B, TβLR1 localization was both
cytoplasmic and nuclear in DD and CT fibroblasts, respectively.
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A

B

Fig 5. TβL1 cellular localization is more cytoplasmic in DD fibroblasts relative to CT
fibroblasts.
(A, B) DD and CT fibroblasts, respectively, were stained with a mouse monoclonal anti-TβL1
antibody and the secondary antibody Alexa Fluor anti-mouse 568. Images were captured by
confocal microscopy using a 20X objective lens. Scale bars: 100 microns.
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A

B

Fig 6. TβLR1 cellular localization is cytoplasmic and nuclear in both DD and CT
fibroblasts.
(A, B) DD and CT fibroblasts, respectively, were stained with a mouse monoclonal anti-TβLR1
antibody, and secondary antibody Alexa Fluor anti-mouse 568. Images were captured by
confocal microscopy using a 20X objective lens. Scale bars: 100 microns.
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Cytokine treatments enhance PLA signals for SUMO1 and TβL1 in both DD and CT
fibroblasts, but not for SUMO1 and TβLR1
To assess whether the SUMOylated TβL1/TβLR1 complex is active in DD and CT
fibroblast, and whether the formation of these complexes changes in response to antiinflammatory cytokines, we conducted PLAs to determine proximity (<40 nm) between TβL1
and SUMO1, as well as TβLR1 and SUMO1 by confocal microscopy. To maximize and stabilize
β-catenin levels and effectively simulate the tissue repair environment in vitro, DD and CT
fibroblasts were treated with Cytomix 2 for 48 hours. PLA signals for TβL1 and SUMO1 were
significantly increased in both DD and CT fibroblasts (P = 0.0002) upon treatment with Cytomix
2 for 48 hours (Figure 7). However, PLA signals for TβLR1 and SUMO1 remained unchanged in
both DD and CT fibroblasts upon treatment with Cytomix 2 for 48 hours (Figure 8).

22

A

B

Fig 7. Interactions between TβL1 and SUMO1 are increased in DD and CT fibroblasts in
response to Cytomix 2.
(A): Transducin β-like 1 (TβL1) and small ubiquitin-like modifier 1 (SUMO1) are visualized by
proximity ligation assay (PLA). Representative images are shown where PLA signal (red)
indicates close proximity (<40 nm) between two proteins. DD and CT fibroblasts were treated
with Cytomix 2, consisting of interleukin-4, interleukin-10, and transforming growth factor-1
beta. Images were captured by confocal microscopy using a 60X objective lens. Scale bars: 50
microns.
(B): Quantification of PLA signal. Data derived from one patient (N=1; n=5). An unpaired t-test
was performed to test for significance between control and Cytomix 2 treatment. Values shown
are mean +/- SD.
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A

B

Fig 8. Interactions between TβLR1 and SUMO1 are unchanged in DD and CT fibroblasts
in response to Cytomix 2.
(A): Transducin β-like receptor-1 (TβLR1) and small ubiquitin-like modifier 1 (SUMO1) are
visualized by proximity ligation assay (PLA). Representative images are shown where PLA
signal (purple) indicates close proximity (<40 nm) between two proteins. DD and CT fibroblasts
were treated with Cytomix 2, consisting of interleukin-4, interleukin-10, and transforming
growth factor-1 beta. Images were captured by confocal microscopy using a 60X objective lens.
Scale bars: 50 microns.
(B): Quantification of PLA signal. Data derived from one patient (N=1; n=5). An unpaired t-test
was performed to test for significance between control and Cytomix 2 treatment. Values shown
are mean +/- SD.
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Cytokine treatments enhance PLA signals for β-catenin and TβL1 as well as β-catenin
and TβLR1 in both DD and CT fibroblasts
To assess whether the SUMOylated TβL1/TβLR1 complex is active in DD and CT
fibroblasts, and whether these complexes interact with β-catenin, PLAs were conducted to
determine proximity (<40 nm) between β-catenin and TβL1 as well as β-catenin and TβLR1 by
confocal microscopy. To maximize and stabilize β-catenin levels and effectively simulate the
tissue repair environment in vitro, DD and CT fibroblasts were treated with Cytomix 2 for 48
hours. PLA signals for TβL1 and β-catenin were significantly increased in both DD and CT
fibroblasts in response to Cytomix 2 treatment for 48 hours (P = 0.0003) (Figure 9). PLA signals
for TβLR1 and β-catenin were also significantly increased in both DD and CT fibroblasts in
response to Cytomix 2 treatment for 48 hours (P< 0.02) (Figure 10).
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A

B

Fig 9. Interactions between TβL1 and β-catenin are increased in DD and CT fibroblasts in
response to Cytomix 2.
(A): Transducin β-like 1 (TβL1) and β-catenin are visualized by proximity ligation assay (PLA).
Representative images are shown where PLA signal (red) indicates close proximity (<40 nm)
between two proteins. DD and CT fibroblasts were treated with Cytomix 2, consisting of
interleukin-4, interleukin-10, and transforming growth factor-1 beta. Images were captured by
confocal microscopy using a 60X objective lens. Scale bars: 50 microns.
(B): Quantification of PLA signal. Data derived from one patient (N=1; n=5). An unpaired t-test
was performed to test for significance between control and Cytomix 2 treatment. Values shown
are mean +/- SD.
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A

B

Fig 10. Interactions between TβLR1 and β-catenin are increased in DD and CT fibroblasts
in response to Cytomix 2.
(A): Transducin β-like receptor-1 (TβLR1) and β-catenin are visualized by proximity ligation
assay (PLA). Representative images are shown where PLA signal (red) indicates close proximity
(<40 nm) between two proteins. DD and CT fibroblasts were treated with Cytomix 2, consisting
of interleukin-4, interleukin-10, and transforming growth factor-1 beta. Images were captured by
confocal microscopy using a 60X objective lens. Scale bars: 50 microns.
(B): Quantification of PLA signal. Data derived from one patient (N=1; n=5). An unpaired t-test
was performed to test for significance between control and Cytomix 2 treatment. Values shown
are mean +/- SD.
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Discussion
In this study, we investigated whether any parallels existed with respect to abnormal βcatenin signalling in DD relative to cancer, in order to assess the feasibility and potential of
cross-purposing anti-cancer drugs to target β-catenin nuclear translocation in fibroproliferative
diseases. We determined that the cellular localization of TβL1 and TβLR1 are primarily
cytoplasmic in DD fibroblasts— translating into an increased availability for the formation of
TβL1/TβLR1/β-catenin complexes that can then translocate into the nucleus relative to CT
fibroblasts. Furthermore, in response to treatment with anti-inflammatory cytokines, DD and CT
fibroblasts both demonstrated increased levels of SUMOylated TβL1 and TβLR1, as well as
higher levels of TβL1 and TβLR1 interactions with β-catenin.

To maximize and stabilize β-catenin levels, DD and CT fibroblasts were treated with
fibrosis-associated cytokines to mimic chronic inflammation. DD fibroblasts demonstrated
higher sensitivity to 48-hour Cytomix 1 treatment, as a modest two-fold increase in β-catenin
levels was observed (Figure 3D) relative to CT fibroblasts (Figure 4D). As mentioned
previously, DD is a hyperproliferative disorder resulting from an exaggerated, abnormal wound
healing response to chronic inflammation7. The heightened sensitivity of DD fibroblasts to proinflammatory cytokines in Figure 3D supports this hypothesis. In response to 48-hour Cytomix 2
treatment, DD fibroblasts experienced a significant 3-fold increase in β-catenin levels (Figure
3D), and CT fibroblasts experienced a significant 2-fold increase (Figure 4D). The increase in βcatenin levels observed after Cytomix 2 treatment may be attributed to TGFβ, as previous studies
determined that fibroblasts treated with TGFβ experienced an increase in β-catenin levels13, 17.
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TGFβ is an important anti-inflammatory cytokine during the wound healing process and is linked
to β-catenin signalling to modulate wound repair and tissue remodeling18.

We determined that upon treatment with Cytomix 2 —consisting of the antiinflammatory fibrosis-associated cytokines IL4, IL10, and TGFβ1— resulted in increased levels
of SUMOylated TβL1 in DD and CT fibroblasts (Figure 7). Furthermore, interactions between
TβL1 and TβLR1 with β-catenin were increased in DD and CT fibroblasts upon treatment with
Cytomix 2 (Figures 9 & 10). To our knowledge, the facilitation of β-catenin nuclear translocation
by the SUMOylated TβL1/TβLR1 has only been studied in the context of cancer cells. Our novel
findings implicating β-catenin nuclear translocation by SUMOylated TβL1/TβLR1 have not yet
been studied in the context of fibrosis and chronic inflammation. Based on these new findings,
along with the role that TGFβ plays in modulating wound repair and tissue remodelling16, 17, 18 —
we hypothesize that the anti-inflammatory cytokines IL4, IL10, and TGFβ1 may contribute to
the transition between the inflammation and proliferation phases in both normal and fibrotic
tissue repair. More specifically, the anti-inflammatory cytokines may lead to increased
interactions between SUMOylated TβL1/TβLR1 and β-catenin, thereby resulting in the βcatenin-mediated transactivation of genes involved in cellular proliferation and wound healing
during normal and abnormal tissue repair (Figure 11).
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Fig 11. The presence of anti-inflammatory cytokines during the transition from the inflammation
to proliferation phase of wound healing mediates β-catenin nuclear translocation as a result of the
SUMOylated TβL1/TβLR1 complex.

Limitations and Future Directions
We have presented here evidence that SUMOylated TβL1 and SUMOylated TβLR1 exist
at higher levels in both DD and CT fibroblasts upon treatment with anti-inflammatory cytokines,
which correlates with increased protein levels of β-catenin. Additionally, TβL1 and TβLR1
interactions with β-catenin are also more abundant as a result. PLAs were used to detect these
protein-protein interactions, as this technique detects proximity between two proteins that is < 40
nm. However, it is important to detect these interactions with other techniques such as
immunoprecipitation, in order to validate our PLA findings. Additionally, in order to directly
confirm the mechanisms behind BC-2059 and its specificity towards targeting specific β-catenin
interactions with SUMOylated TβL1 and TβLR1 — it is important to test whether interactions
between TβL1 and TβLR1 with β-catenin are effectively disrupted in drug-treated DD
fibroblasts.
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The protein-protein interactions were primarily detected in fibroblasts cultured in vitro,
and this may present a limitation of this study. Although the levels of β-catenin were stabilized
through treatments with fibrosis-associated cytokines in order to mimic the tissue repair
environment and maintain physiological relevance — these findings can be strengthened by
moving towards an ex vivo experimental approach. Performing immunostaining and PLAs in
fresh palmar fascia tissue ex vivo may strengthen our findings by providing increased
physiological relevance 27.

Conclusion
In summary, we have presented evidence of the specific mechanisms that may be
involved in β-catenin nuclear translocation during the anti-inflammatory phase of tissue repair.
Our novel findings present the SUMOylated TβL1/TβLR1 complex as a new therapeutic target
for DD and other fibroproliferative diseases. Small molecule inhibitors such as BC2059 that
disrupt interactions between SUMOylated TβL1/TβLR1 and β-catenin are in development for the
treatment of cancer and are already undergoing phase-I clinical trials28. Our observations here
show that similar mechanisms may be involved during the abnormal tissue repair process
associated with the development of DD. At present, there are no therapies that focus on targeting
early disease development and preventing post-surgical disease recurrence in DD. The results of
this study identify SUMOylated TβL1/TβLR1 interactions with β-catenin as a novel therapeutic
target for DD and other fibroproliferative diseases.
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